Hormonal
Anti-obesity medications (AOMs) combined with lifestyle modifications produce greater and more sustained weight loss (5-23%) compared to lifestyle changes alone, with specific agents like semaglutide and tirzepatide showing superior efficacy.
If you have obesity, lifestyle changes alone are often insufficient for long-term success due to biological factors. FDA-approved medications like semaglutide or tirzepatide, when combined with lifestyle changes, can produce significant weight loss (16-23%). These medications are intended for long-term use. Discuss with your doctor if you are a candidate, considering potential side effects and costs.
AOMs combined with lifestyle modifications can produce greater, more sustained weight-loss compared with lifestyle changes alone and may be an additional option for patients.
Why this rating
Based on clinical trials and FDA-approved data cited in the review.
Source
Setting Expectations When Prescribing Medication for the Treatment of Patients With Obesity
Angela Fitch · Mayo Clinic Proceedings Innovations Quality & Outcomes · 2025
DOI 10.1016/j.mayocpiqo.2025.100621
More from this paper
- Achieving 5-10% weight loss through any method (including medication) is associated with significant improvements in obesity-related comorbidities, including type 2 diabetes prevention, cardiovascular risk reduction, and NAFLD resolution.Good
- Off-label use of generic medications (e.g., metformin, SGLT2 inhibitors) or compounded GLP-1 agonists carries risks of unknown efficacy, safety issues, and potential adverse events compared to FDA-approved anti-obesity medications.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →